Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor

Int J Pharm. 2005 Jul 25;298(2):378-83. doi: 10.1016/j.ijpharm.2005.03.027.

Abstract

The aim of this work was to develop a formulation for Z-DEVD-FMK, a peptide which is a caspase inhibitor and has been used in experimental animal studies for a decade. Peptide loaded chitosan nanoparticles were obtained by ionotropic gelation process and Z-DEVD-FMK was quantified by an HPLC method. The influence of the initial peptide concentration on the nanoparticle characteristics and release behavior was evaluated. The CS nanoparticles have a particle diameter (Z-average) ranging from approximately 313-412 nm and a positive zeta potential (20-28 mV). The formulation with the initial peptide concentration of 400 ng/ml provided the highest loading capacity (0.46%) and the highest extent of release (65% at 24 h) suggesting the possibility to achieve a therapeutic dose. According to the data obtained, this chitosan-based nanotechnology opens new and interesting perspectives for anticaspase activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Caspase Inhibitors*
  • Chemical Phenomena
  • Chemistry, Physical
  • Chitosan / chemistry*
  • Chromatography, High Pressure Liquid
  • Electrochemistry
  • Gels
  • Microscopy, Electron, Transmission
  • Nanostructures*
  • Oligopeptides / administration & dosage*
  • Oligopeptides / chemistry
  • Particle Size
  • Protease Inhibitors / administration & dosage*
  • Protease Inhibitors / chemistry

Substances

  • Caspase Inhibitors
  • Gels
  • Oligopeptides
  • Protease Inhibitors
  • benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone
  • Chitosan